Two SPAC’d biotechs raise ad­di­tion­al mon­ey as Bi­hua Chen’s blank check clos­es $184M IPO

The post-SPAC life isn’t all too great for most biotech com­pa­nies — or those in oth­er in­dus­tries, for that mat­ter. But some drug de­vel­op­ers that went the blank-check route have found green­er pas­tures in re­cent months, with two of them an­nounc­ing large fi­nanc­ings this week.

This is amid a sec­ond biotech SPAC from Bi­hua Chen, founder of Cor­morant As­set Man­age­ment. Known as He­lix Ac­qui­si­tion Corp. II $HLXB, the SPAC closed a $184 mil­lion ini­tial pub­lic of­fer­ing on Wednes­day. It will hunt for a biotech or oth­er health­care busi­ness to com­bine with af­ter He­lix I found suc­cess with Moon­Lake Im­munother­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER